Ivonescimab

Modify Date: 2024-04-05 17:20:48

Use of Ivonescimab

Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research[1][2][3].

Name	Ivonescimab

Description	Ivonescimab (AK112) is a PD-1/VEGF Bispecific Antibody. Ivonescimab can be used for cancer research[1][2][3].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1 Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR
In Vitro	Ivonescimab 可与 PD-1 和 VEGFA 结合，EC50 分别为 0.06 和 0.036 nM[2]。 Ivonescimab 可与 VEGF 形成可溶性复合物 (通过 SEC-HPLC 检测)[2]。
References	[1]. Coward J, et al. Efficacy and safety of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with platinum-resistant/refractory epithelial ovarian cancer in a Phase 1 study. Journal for Immuno Therapy of Cancer 2021;9: [2]. Zhong T, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies. Journal for Immuno Therapy of Cancer. 2022;10: [3]. Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. Journal for Immuno Therapy of Cancer. 2022;10:e005517.

No Any Chemical & Physical Properties

Dichloromethane
CAS#:75-09-2

Polyacrylic acid
CAS#:9003-01-4

sodium carbonate
CAS#:497-19-8

Silicon dioxide
CAS#:7631-86-9

Triethanolamine
CAS#:102-71-6

Demeton
CAS#:126-75-0

Water
CAS#:7732-18-5

Diclofenac sodium
CAS#:15307-79-6

Budesonide
CAS#:51372-29-3